PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks and other complications of their blood vessels. New therapies are needed to prevent this complication. The purpose of this study is to establish the role of the medication pioglitazone in improving the function of the blood vessels and heart and decreasing the risk of future atherosclerosis development in individuals with rheumatoid arthritis. As a secondary aim-point, we will evaluate the efficacy of pioglitazone in improving rheumatoid arthritis disease activity and markers of inflammation.

Key facts

Study ID

NCT00554853

Run by

University of Michigan

People needed

143

Starts

2007-11-01

Expected to finish

2013-01-01

Last updated by the study team

2017-02-02

Who can join

Age: 21 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women on adequate contraception if they are of child-bearing age.
• Meet revised ACR criteria for RA.
• Stable doses of DMARDS,biologic agents and or corticosteroids for at least 3 months.

You may not qualify if…

• Pregnant or lactating women.
• Current smokers or individuals who smoked in the last 6 months.
• Diagnosis of Diabetes, heart failure, or infection.
• Current diagnosis of malignant disease except for basal cell or squamous cell carcinoma of the skin.
• No active liver disease.
• No cholesterol-lowering medications or oral hypoglycemic agents.

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.